ABK Biomedical Inc.,announced today it is consolidating its operations to Halifax. Heading up this consolidation will be ABK Biomedical’s new Chief Executive Officer, Dr. Bob Abraham. As an ABK Biomedical co-founder, Dr. Abraham also serves as Chief Medical Officer and is a member of its Board of Directors.
The company focus to Halifax and CEO appointment follow ABK Biomedical’s recent award of $2.14M from Atlantic Canada Opportunities Agency (ACOA), under the Atlantic Innovation Fund (AIF). The AIF award will enable ABK to simplify and enhance chemotherapy and radiotherapy for cancer patients with ABK’s novel radiopaque embolic beads. In addition to ACOA’s support, ABK has received funding through strong local, national and US based angel and institutional investment. The commitment of the private investors, with the leverage from AIF funding will fuel ABK’s lead product first-in-human trials as well as advancing a robust pipeline of products.
In his new role as CEO, Dr. Abraham will steer ABK through clinical validation, regulatory approval and market readiness. Dr. Abraham will also lead the expansion of the company’s product pipeline as ABK Biomedical looks to develop next generation resorbable, radiopaque, drug eluting and radioembolic agents to be used for chemoembolization and radioembolization treatment of liver cancer.
“As a nationally recognized embolization expert, we are delighted to have Dr. Abraham as our new, full-time CEO,” said Dr. Aaron Berez, Chairman of the Board of ABK Biomedical. “His experience as a clinician, entrepreneur and med tech investor as well as his dedication to patients and passion for innovation make him the ideal candidate to lead ABK.”
“Having the full ABK Biomedical team, including product engineering, quality management system (QMS), regulatory, and R&D, together in our Halifax facilities supports our commitment to bringing our novel embolic systems to patients as quickly as possible,” said Dr. Abraham.
Dr. Abraham has spent more than 20 years as a practicing clinician and interventional radiologist at Capital Health (CDHA). He has successfully licensed catheter innovations and established the Uterine Fibroid Embolization (UFE) program at QEII Health Sciences Centre and IWK in 2001. Dr. Abraham earned his medical degree from Dalhousie University in Halifax, interned at St. Paul’s Hospital in Vancouver, returned to complete specialty training in Diagnostic Imaging at Dalhousie University and then completed sub-specialty training in Interventional Radiology at the Royal Melbourne Hospital in Australia. He is a Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPC), a past Chair of the Royal College's exam in Diagnostic Radiology, and Past President for the Canadian Association of Radiologists (CIRA).
Founded in 2012, ABK Biomedical Inc. is pursuing development, production and sale of embolic agents and peripheral vascular delivery devices. The company’s radiopaque pipeline products, while still investigational, have the potential to provide simpler, safer and more cost effective solutions for treating hypervascular tumors and diseases.